Publications by authors named "R Boccia"
Background: To compare accuracy in intraocular lens (IOL) power calculation in eyes undergoing combined cataract and Descemet stripping and automated endothelial keratoplasty (C-DSAEK) surgery of the following formulas: Barrett Universal II, EVO, Haigis, Hoffer Q, Holladay 2, Kane and SRK/T.
Methods: 72 eyes from 72 patients (38 males, (53%)) with a mean age 68.08 ± 8.
Erythropoiesis-stimulating agents (ESAs) are the first-line treatment option for anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS). A systematic literature review was conducted to identify evidence of the association between prognostic factors and ESA response/failure in LR-MDS. MEDLINE, Embase, and relevant conferences were searched systematically for studies assessing the association between prognostic factors and ESA response/failure in adult patients.
View Article and Find Full Text PDFArticle Synopsis
- Ruxolitinib (RUX) is an FDA-approved medication for treating conditions like myelofibrosis and polycythemia vera, and this study examines its effectiveness combined with lenalidomide (LEN) in patients with progressing multiple myeloma who previously received other treatments.
- The study involved a phase I trial where participants, after failing initial therapies, received a combination of RUX and methylprednisolone (MP), and those with disease progression were given LEN as well.
- Of the 29 participants, there was a 31% overall response rate to the initial RUX and MP treatment, with some showing varying degrees of disease stabilization, but also highlighted the challenges in managing advanced
Background And Objective: Iron deficiency is the most common cause of anemia. We compared the effect of ferric carboxymaltose (FCM), low-dose intravenous (IV) iron (LDI), and iron sucrose on total cost of care in patients with iron-deficiency anemia (IDA) from a US health plan perspective.
Methods: We conducted a retrospective claims analysis using the IQVIA PharMetrics Plus database.
Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) may have distinctive pathophysiological features in type 1 diabetes (T1D). We evaluated the independent role of blood glucose control on MASLD in T1D.
Methods: In a cross-sectional study on 659 T1D adult patients, MASLD was assessed by the Fatty Liver Index (FLI) and the Hepatic Steatosis Index (HSI).